THE HUMANISTIC AND ECONOMIC BURDEN OF IRRITABLE BOWEL SYNDROME WITH DIARRHOEA (IBS-D) BY DISEASE SEVERITY AMONG PATIENTS IN THE EU5 REGION
Author(s)
Flores NM1, Tucker C2, Carson RT3, Abel JL3, Liebert R4
1Kantar Health, Foster City, CA, USA, 2Allergan plc, Marlow, Buckinghamshire, UK, 3Allergan plc, Jersey City, NJ, USA, 4Kantar Health, New York, NY, USA
OBJECTIVES: To assess the burden of IBS-D on health-related quality of life (HRQoL), activity impairment and healthcare resource utilisation (HCRU) based on disease severity among adults in the EU5 (Spain, France, Italy, Germany and United Kingdom). METHODS: IBS-D patients were identified from the EU5 2013 National Health and Wellness Survey, a self-administered, internet-based general health survey. Patients reported the frequency and nature of their IBS symptoms and disease severity (mild/moderate/severe). HRQoL, activity impairment and HCRU were assessed using the Short Form-36 version 2 physical and mental component summary scores (PCS, MCS; range 0–100), Work Productivity and Activity Impairment Questionnaire General Health Version (higher percentages indicate greater impairment) and number of patient-reported visits to any healthcare provider in the past 6 months, respectively. Multivariable generalised linear models assessed HRQoL, activity impairment and HCRU by IBS-D severity, controlling for demographic and health characteristics. RESULTS: CONCLUSIONS: Patients with more severe IBS-D experience greater impairments in HRQoL and daily activities, and higher HCRU, representing a substantial burden of illness and highlighting the need for effective treatments to manage IBS-D symptoms.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PGI31
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Gastrointestinal Disorders